Literature DB >> 20692258

Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654.

Klaus Dittmann1, Claus Mayer, Birgit Fehrenbacher, Martin Schaller, Rainer Kehlbach, H Peter Rodemann.   

Abstract

Nuclear localisation of EGFR is associated with treatment resistance of tumor cells. The aim of this study was to identify molecular targets to block nuclear shuttling of EGFR. Mutation of Thr654, located within the putative EGFR NLS demonstrated that phosphorylation of this residue is essential for nuclear EGFR shuttling following irradiation. Deletion of Thr654 blocked nuclear transport of EGFR, whereas mutation to Glu increased shuttling. Treatment with a peptide, corresponding to the phosphorylated NLS, abolished nuclear EGFR transport and reduced radiation-induced activation of DNA-PK, essential for DNA-repair. In accordance with that, lack of nuclear EGFR increased residual DNA damage in tumor cells and reduced cellular survival following irradiation. Blockage of nuclear EGFR shuttling may be a new strategy to fight treatment resistance.
Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692258     DOI: 10.1016/j.febslet.2010.08.005

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

1.  FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells.

Authors:  Sridhar Muthusami; D S Prabakaran; Jae-Ran Yu; Woo-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-24       Impact factor: 4.553

Review 2.  Receptor tyrosine kinases in the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-10-01       Impact factor: 10.005

Review 3.  On mammary gland growth factors: roles in normal development and in cancer.

Authors:  Mien-Chie Hung
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-08-01       Impact factor: 10.005

Review 4.  Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.

Authors:  Woody Han; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

Review 5.  EGFR signaling and autophagy dependence for growth, survival, and therapy resistance.

Authors:  Barry Jutten; Kasper M A Rouschop
Journal:  Cell Cycle       Date:  2013-12-13       Impact factor: 4.534

Review 6.  Non-canonical signaling mode of the epidermal growth factor receptor family.

Authors:  Heng-Huan Lee; Ying-Nai Wang; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

Review 7.  The nuclear epidermal growth factor receptor signaling network and its role in cancer.

Authors:  Toni M Brand; Mari Iida; Chunrong Li; Deric L Wheeler
Journal:  Discov Med       Date:  2011-11       Impact factor: 2.970

8.  In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Authors:  Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

9.  PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.

Authors:  Hong-Yi Kuo; Yen-Sung Huang; Chin-Hsiu Tseng; Yi-Chen Chen; Yu-Wei Chang; Hsiu-Ming Shih; Cheng-Wen Wu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells.

Authors:  Ye Yuan; Si Chen; Tatjana Paunesku; Sophie Charlotte Gleber; William C Liu; Caroline B Doty; Rachel Mak; Junjing Deng; Qiaoling Jin; Barry Lai; Keith Brister; Claus Flachenecker; Chris Jacobsen; Stefan Vogt; Gayle E Woloschak
Journal:  ACS Nano       Date:  2013-11-27       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.